Neurocrine Biosciences INC Form 4 insider transactions

Neurocrine Biosciences Director Leslie V. Norwalk acquired 1,659 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director George J. Morrow acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Johanna Mercier acquired 3,318 shares of common stock through the vesting of restricted stock units.

Neurocrine Biosciences Director Gary Lyons acquired 1,659 shares of common stock through the vesting of restricted stock units.

Director Kevin Gorman exercised options for 205,088 shares and sold a total of 245,088 shares of Neurocrine Biosciences.

Neurocrine Biosciences Director Richard Pops exercised 15,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences Director Leslie V. Norwalk sold 3,810 shares of common stock for approximately $155.01 per share, totaling over $590,000, as part of a pre-arranged trading plan.

Neurocrine Biosciences CFO Matt Abernethy reported a gift of 2,249 common shares, reducing his direct beneficial ownership.

Neurocrine Biosciences Chief Scientific Officer Jude Onyia gifted 3,110 shares of common stock, reducing his direct beneficial ownership.

Neurocrine Biosciences Chief Corporate Affairs Officer David W. Boyer acquired shares through RSU vesting and had shares withheld for tax obligations.

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, reported the future vesting of restricted stock units and subsequent share withholding for tax obligations.

Neurocrine Biosciences' CFO, Matt Abernethy, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Neurocrine Biosciences' Chief Human Resources Officer, Julie Cooke, reported the vesting of 1,741 restricted stock units and the withholding of 997 shares for tax obligations.

Neurocrine Biosciences' Chief Regulatory Officer, Ingrid Delaet, reported the vesting of 801 restricted stock units and the withholding of 475 shares for tax obligations.

Neurocrine Biosciences CEO Kyle Gano reported the vesting of 2,927 restricted stock units and the withholding of 1,580 shares for tax obligations.

Neurocrine Biosciences Director Kevin Gorman reported the vesting of restricted stock units and subsequent share withholding for tax obligations.

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported the routine vesting of restricted stock units and subsequent tax withholding on January 31, 2026.

Neurocrine Biosciences CEO Kyle Gano exercised stock options and sold 36,400 shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, amended a previous filing to correct the number of stock options exercised on November 28, 2025.

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, exercised 3,349 stock options at $35.99 per share, increasing his direct common stock holdings to 46,754 shares.

A Neurocrine Biosciences director exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, executed a pre-arranged 10b5-1 plan, exercising stock options and selling 4,376 common shares.

Neurocrine Biosciences Director Gary A. Lyons exercised options and sold 15,000 shares of common stock for approximately $152.61 per share under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, reported the vesting of 4,426 restricted stock units and the subsequent withholding of 2,248 shares for tax obligations.

Neurocrine Biosciences Director George J. Morrow exercised options and sold 15,000 shares of common stock for approximately $143.37 per share under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences Director William H. Rastetter exercised options and sold 18,000 shares of common stock under a pre-arranged 10b5-1 trading plan.

Neurocrine Biosciences CEO Kyle Gano reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Neurocrine Biosciences' Chief Scientific Officer, Jude Onyia, gifted 1,470 shares of common stock in a pre-planned transaction.